Scarica l'app Stockscreener
1.90
7.32%
-0.15
Pre-mercato:
1.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Atossa CEO to join Harvard panel on aging disea... - Pluang
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging - Yahoo Finance
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Salinas Californian
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) dropped from S&P Global BMI Index - marketscreener.com
Atossa posts updated corporate presentation highlighting (Z)-Endoxifen programs, $26.1M cash - TradingView
Debt to equity ratio of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBIT forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Atossa Therapeutics (ATOS) Holds Steady at $2.52 — Awaiting Catalyst Within $2.39–$2.65 RangeTPO Profile - siam.in
Atossa Therapeutics (ATOS) Q2 2026 Earnings: Narrower-than-Expected Loss Reflects Cost ContainmentEarnings Quality Score - dars.gov.et
Atossa Therapeutics explores collaborative clinical research for (Z)-endoxifen applications - Traders Union
Atossa (ATOS) Results Breakdown: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: Shares Rise 2.76% at the CloseEarnings Power Value - vinanet.vn
Atossa Therapeutics advances investigational Z-endoxifen research for broader DMD applications - Traders Union
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - Sahm
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
ATOS: Multiple Catalysts Converge in 2H26 - Smartkarma
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Atossa Therapeutics pursues ESR1 mutation research to tackle endocrine resistance in breast cancer - Traders Union
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Atossa Therapeutics shifts clinical focus to pre-surgical breast cancer patients - Traders Union
Atossa Therapeutics (ATOS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock SlipsQuarterly Profit Report - dars.gov.et
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Atossa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Q2 net loss, financing and (Z)-endoxifen Phase 2 progress - TradingView
Atossa Therapeutics reports Q2 2026 results, ad... - Pluang
Atossa Therapeutics (ATOS) Dips 2.48% to $2.36 as Stock Tests Key Support ZoneWyckoff Upthrust - dars.gov.et
Atossa Therapeutics Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView
Atossa Therapeutics investigates (Z)-endoxifen for McCune-Albright syndrome and endocrine disorders - tradersunion.com
Atossa Therapeutics (ATOS) Advances Clinical Pipeline Amid Valua - GuruFocus
Form 8K Atossa Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
Atossa Therapeutics Q2 net loss widens on lower interest income - TradingView
Atossa Therapeutics reports Q2 2026 net loss $8.5M, cash $26.1M; advances (Z)-endoxifen programs - TradingView
ATOS: Q2 2026 net loss was $8.5M; (Z)-endoxifen programs advanced and $4.5M in new capital raised - TradingView
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary - TradingView
Atossa Therapeutics (NASDAQ: ATOS) posts $18.1M loss, flags going concern risk - Stock Titan
Atossa Therapeutics strengthens pipeline with new data on Z-endoxifen breast cancer therapy - tradersunion.com
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
Atossa Therapeutics founder to be selected as NIAID director — report - Endpoints News
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Atossa Therapeutics advances rare disease pipeline with (Z)-endoxifen strategy - Traders Union
ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Narrows Loss Despite No Revenue; Stock Down 5.48%Financial Health Score - vinanet.vn
Atossa Therapeutics advances biomarker-driven Z-endoxifen treatment for breast cancer - Traders Union
ATOS Q1 2026 Earnings: Narrowed Loss Beats Estimates by 82% While Shares SlipProfit Guidance Range - careplusvn.com
Atossa Therapeutics (ATOS) Focuses on Execution Amid Challenging Valuation and Mixed Guru Interest - GuruFocus
Atossa study shows preclinical activity in breast cancer models By Investing.com - Investing.com South Africa
Atossa Therapeutics (ATOS) Unveils Promising Preclinical Breast Cancer Study Amidst Challenging Valuation - GuruFocus
Atossa study shows preclinical activity in breast cancer models - Investing.com
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - Morningstar
Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atossa Therapeutics (ATOS) Gains 4.6%: Biotech Stock Tests Key ResistanceCash Flow Strong Stocks - careplusvn.com
TradingKey - TradingKey
Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Amidst Pre-Revenue StageEPS Consistency Score - careplusvn.com
Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ATOS|Atossa Therapeutics Inc|Price:2.295|Chg%:-0.115 - TradingKey
ATOSSA THERAPEUTICS, INC. advances omics and organoid research in rare cancer field - Traders Union
Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxi - GuruFocus
Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxifen in Rare Disease Treatment - GuruFocus
Atossa Therapeutics highlights (Z)-endoxifen's dual action for rare McCune-Albright Syndrome treatment. - Pluang
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - PR Newswire
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Price to sales forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Enterprise value to revenue forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):